S-(+)-3,5-二氟扁桃酸 | 209982-91-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: S-(+)-3,5-二氟扁桃酸
• 中文别名: (S)-2-(3,5-二氟苯基)-2-羟基乙酸
• 英文名称: S-(+)-3,5-difluoromandelic acid
• 英文别名: (S)-3,5-difluoromandelic acid；(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetic acid
• CAS: 209982-91-2
• 化学式: C₈H₆F₂O₃
• 分子量: 188.131
• InChiKey: PHMLPPFFMSRWBK-ZETCQYMHSA-N

物化性质

• 沸点：
  306.5±37.0 °C(Predicted)
• 密度：
  1.522±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  S-(+)-3,5-二氟扁桃酸 、 2,3,4,5-tetrahydro-3-methyl-5(R,S)-[[(2S)-2-amino-1-oxopropyl]amino]-2-(1-methylethyl)-1H-2,3-benzodiazepin-1,4-dione 在 N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide polymer 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成
  参考文献：
  名称：

  2,3-Benzodiazepin-1,4-diones as peptidomimetic inhibitors of γ-secretase

  摘要：

  2,3-Benzodiazepin-1,4-diones were designed as peptidomimetics at the carboxy terminus of hydroxyamides. Inhibition of brain Abeta production was improved by one of the compounds containing constrained modification. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.056
• 作为产物：
  描述：

  Methyl S-(+/-)-3,5-difluoromandelate 在 lithium hydroxide 作用下， 以 aqueous THF 为溶剂， 生成 S-(+)-3,5-二氟扁桃酸
  参考文献：
  名称：

  Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds

  摘要：

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。

  公开号：

  US06509331B1

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：Athena Neurosciences, Inc.

  公开号：US06506782B1

  公开（公告）日：2003-01-14

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。
• Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US06509331B1

  公开（公告）日：2003-01-21

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。
• Enzymatic Resolution by a<scp>d</scp>-Lactate Oxidase Catalyzed Reaction for (<i>S</i>)-2-Hydroxycarboxylic Acids
  作者：Binbin Sheng、Jing Xu、Yongsheng Ge、Shuo Zhang、Danqi Wang、Chao Gao、Cuiqing Ma、Ping Xu

  DOI：10.1002/cctc.201600536

  日期：2016.8.22

  Oxidase‐catalyzed kinetic resolution is important for the production of enantiopure 2‐hydroxycarboxylic acids (2‐HAs), which are versatile building blocks for the synthesis of many significant compounds. However, in contrast to that of (R)‐2‐HAs, the production of (S)‐2‐HA is challenging because of the lack of related oxidases. Herein, suitable enzymes were screened systematically through the analysis

  氧化酶催化的动力学拆分对于生产对映体纯的2-羟基羧酸（2-HAs）非常重要，这是合成许多重要化合物的通用构建基块。但是，与（R）-2-HAs相比，由于缺乏相关的氧化酶，（S）-2-HA的生产具有挑战性。在这里，通过分析许多推定的d-乳酸氧化酶序列并鉴定一些所需的特性，系统地筛选了合适的酶。最后，选择氧化葡糖杆菌621H中的d-乳酸氧化酶，具有良好的溶解度，底物谱宽，立体选择性高等优点，可将2-HAs分解为（S）-2-HAs。使用该d-乳酸氧化酶成功生产了多种（S）-2-HAs，其对映体过量值极佳（> 99％）。提出的目标生物催化筛选标准和方法为生产旋光活性化学物质（S）-2-HAs提供了指导原则。
• Biological reagents and methods for determining the mechanism in the generation of &bgr;-amyloid peptide
  申请人：Elan Pharmaceuticals Inc.

  公开号：US06486350B1

  公开（公告）日：2002-11-26

  Disclosed are biological reagents which comprise compounds that inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in determining the cellular mechanism involved in the generation of &bgr;-amyloid peptide.

  本发明涉及生物试剂，其中包括抑制β-淀粉样肽释放和/或其合成的化合物，因此在确定参与β-淀粉样肽生成的细胞机制方面具有实用性。